<?xml version="1.0" encoding="UTF-8"?>
<xml>
<records>
<record>
  <contributors>
    <authors>
      <author>Rubio-Briones, J.</author>
      <author>Borque, A.</author>
      <author>Esteban, L.M.</author>
      <author>Casanova, J.</author>
      <author>Fernandez-Serra, A.</author>
      <author>Rubio, L.</author>
      <author>Casanova-Salas, I.</author>
      <author>Sanz, G.</author>
      <author>Domínguez-Escrig, J.</author>
      <author>Collado, A.</author>
      <author>Gómez-Ferrer, A.</author>
      <author>Iborra, I.</author>
      <author>Ramírez-Backhaus, M.</author>
      <author>Martínez, F.</author>
      <author>Calatrava, A.</author>
      <author>Lopez-Guerrero, J.</author>
    </authors>
  </contributors>
  <titles>
    <title>Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy</title>
    <secondary-title>BMC CANCER</secondary-title>
  </titles>
  <doi>10.1186/s12885-015-1623-0</doi>
  <pages/>
  <volume/>
  <number/>
  <dates>
    <year>2015</year>
    <pub-dates>
      <date>2015</date>
    </pub-dates>
  </dates>
  <abstract/>
</record>

</records>
</xml>